Condition: Arteriovenous Malformations · Sponsor: Centre Hospitalier Universitaire, Amiens
The aim of the study is to evaluate the efficacy and safety of sirolimus (oral form), to decrease the volume and symptoms due to superficial arteriovenous malformations (AVM). Sirolimus has properties that reduce the activity of the immune system (immunosuppressant), to fight against the proliferation of cancer cells (anti- tumor) and also reduce the proliferation of blood vessels (anti -vascular). Sirolimus is primarily used in transplant patients to prevent organ transplant rejection. Many animal and laboratory studies were carried out and demonstrate in particular the activity of sirolimus on vessels. It is this anti- vascular effect that could help treat arteriovenous malformations.
This description comes directly from the study's public registry record.
Bernard DEVAUCHELLE, MD, PhD · +33322668325 · devauchelle.bernard@chu-amiens.fr
Sylvie TESTELIN, MD, PhD · testelin.sylvie@chu-amiens.fr
Always discuss trial participation with your own doctor first.
| UCL | Brussels, Belgium | Not Yet Recruiting |
| CHU Amiens | Amiens, France | Recruiting |
| CHU Bordeaux | Bordeaux, France | Not Yet Recruiting |
| CHU Dijon | Dijon, France | Recruiting |
| CHRU Lille | Lille, France | Not Yet Recruiting |
| HCL Lyon | Lyon, France | Recruiting |
| APHM | Marseille, France | Not Yet Recruiting |
| CHU Montpellier | Montpellier, France | Not Yet Recruiting |
| CHU Nancy | Nancy, France | Not Yet Recruiting |
| CHU Nice | Nice, France | Not Yet Recruiting |
| APHP | Paris, France | Not Yet Recruiting |
| CHU Strasbourg | Strasbourg, France | Not Yet Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02042326